Singapore’s Aslan Pharma lines up an $86M IPO to fund pivotal cancer drug studies

With its lead oncology drug in a pivotal study for biliary tract cancer and a slate of key catalysts coming up in other trials, Singapore-based Aslan Pharmaceuticals has filed for an IPO on Nasdaq, with plans to raise around $86 million. Helmed by Carl …
( read original story …)

Search your Hotel